3/13
02:48 pm
clnn
Clene (CLNN) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $48.00 price target on the stock.
Medium
Report
Clene (CLNN) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $48.00 price target on the stock.
3/12
04:57 pm
clnn
Clene (CLNN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
Medium
Report
Clene (CLNN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
3/12
08:38 am
clnn
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights [Yahoo! Finance]
Medium
Report
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights [Yahoo! Finance]
3/12
08:00 am
clnn
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Medium
Report
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
2/26
04:14 pm
clnn
Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway [Yahoo! Finance]
Low
Report
Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway [Yahoo! Finance]
2/24
08:00 am
clnn
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
Medium
Report
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
2/19
08:53 am
clnn
Clene to Present at the Emerging Growth Conference [Yahoo! Finance]
Medium
Report
Clene to Present at the Emerging Growth Conference [Yahoo! Finance]
2/19
08:30 am
clnn
Clene to Present at the Emerging Growth Conference
Medium
Report
Clene to Present at the Emerging Growth Conference
1/16
08:30 am
clnn
Clene to Present at the Emerging Growth Conference
Low
Report
Clene to Present at the Emerging Growth Conference
1/12
08:30 am
clnn
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
High
Report
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
1/9
09:40 am
clnn
Clene announces registered direct offering of over $28M [Seeking Alpha]
Medium
Report
Clene announces registered direct offering of over $28M [Seeking Alpha]
1/9
09:00 am
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
High
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
1/9
08:30 am
clnn
Clene Announces Registered Direct Offering of Over $28 Million
High
Report
Clene Announces Registered Direct Offering of Over $28 Million